Humatica’s new whitepaper on Buy & Build. Download now

closeicon

Humatica’s new whitepaper on Buy & Build. Download now

closeicon

The Third Wave – catching the next
wave of value creation

ndetails

Based on a request from Limited Partners and General Partners, Humatica initiated an ambitious study to understand the current state of the art in organizational due diligence. We set out to develop a better approach to getting deeper insights on management practices in an acquisition target prior to signing.

Private equity today is a mature industry with many players having entered the lucrative field in the last 10 years, during which returns have steadily declined. Increased competition has driven up both target prices and risks taken to realise a reasonable return.

Investors have reacted by focusing on enhancing performance through the engagement of «operating partners» who have the functional skills as well as operational and leadership experience to drive improvements in portfolio companies. Further, extensive effort is made pre-deal to assess potential risks in the due diligence phase including market, financial, and legal aspects. However, these methods are backward looking and provide limited insights about the target company’s ability to master new challenges and increase value in the future.

To download our Third Wave Study, please complete your details on the form below:

Activate organizations. Deliver alpha.

Download our Third Wave Study by completing the form.

Please fill all relevant fields. *Indicates required details

I agree to Humatica’s Data Protection Policy and that Humatica may use my data to contact me via email.

Enter Security code*

01O8

Related Insights

Ignite Your Sales Engine to Turbocharge Growth – An Introduction (1/6)
08 Sep, 2021 By Humatica

Ignite Your Sales Engine to Turbocharge Growth – An Introduction (1/6)

Sales is an essential function of every business. An effective Sales Engine can supercharge the value generated from your products and services. But Sales teams…

Read more arrowicon
Interview with Dr. Thomas Costa of Coventya
28 Jul, 2021 By Humatica

Interview with Dr. Thomas Costa of Coventya

In the new episode of the alpha Talks Podcast, Enno Krey speaks to Dr. Thomas Costa, former CEO of Coventya, a leading international specialty chemicals…

Read more arrowicon
Assessing Organizational Readiness Pre-deal: Deal Makers Need More Than 10 Questions
19 Jul, 2021 By Humatica

Assessing Organizational Readiness Pre-deal: Deal Makers Need More Than 10 Questions

A side-effect of full-priced markets and the industrialisation of private equity is funds looking to upgrade and standardize their deal processes – the way they…

Read more arrowicon

Subscribe to our Monthly Newsletter and other News Updates

Receive our news and valuable perspectives on organizational effectiveness each month.

I agree to Humatica’s Data Protection Policy and that Humatica may use my data to contact me via email.